BCI Neural Implant in China (2026): China's First Fully Implantable Brain-Computer Interface Trial Begins

Brain-Computer Interface Treatment in China: Complete Guide (2026)

What Is a BCI Neural Implant?

A brain-computer interface is a system that reads electrical signals from the brain and translates them into commands for external devices — computers, wheelchairs, prosthetic limbs, or functional electrical stimulation (FES) devices that reanimate paralyzed muscles. For patients with severe paralysis from spinal cord injury, stroke, ALS, or muscular dystrophy, a BCI offers something no drug can: a direct path from thought to action.

There are three main categories:

• Non-invasive: EEG caps placed on the scalp. Signal quality is lower but no surgery required. Used in rehabilitation clinics worldwide.
• Semi-invasive: Electrodes placed on the surface of the brain (epidural or subdural) without penetrating brain tissue. Better signal than EEG, lower surgical risk than full implantation.
• Fully implantable (invasive): Electrodes penetrate brain tissue. Highest signal resolution. The focus of this article.

China's two main commercial/in-trial players are NeuroXess (backed by the Shanghai government, listed on Shanghai STAR Market) and Neurecell (NMPA-approved, ACL-BCI-1 device). Both companies have been implanting patients since 2024–2025, primarily under compassionate use or early-access programs.

How BCI Implantation Works

The surgical procedure for a fully implantable BCI typically involves:

• A craniotomy (skull opening) — typically 4–8 cm depending on the device
• Placement of an electrode array onto the motor cortex surface or within brain tissue
• Tunneling of leads under the skin to a chest-implanted signal processor
• The processor wirelessly transmits neural data to an external computer or FES device
• Surgery duration: 4–8 hours under general anesthesia
• Hospital stay: 5–10 days for initial recovery and calibration

Who Is Eligible for BCI Implantation in China?

Current trial and approved indications in China include:

• Spinal cord injury patients with preserved motor cortex function (ASIA A–C classification)
• Stroke patients with hemiplegia who have completed standard rehabilitation without adequate recovery
• ALS patients with preserved cognition — BCI as augmentative communication device
• Muscular dystrophy patients with progressive loss of hand function

Candidates must be between 18 and 65 years of age, have adequate cognitive function to learn BCI control, and have no active infections or severe medical comorbidities that would make neurosurgery unsafe.

China's BCI Advantages for International Patients

• Earlier access: China's NMPA approved the first commercial BCI device in the world (March 2026). Comparable devices are still in FDA review in the US.
• Cost advantage: Even accounting for surgery, device, and hospitalization, BCI treatment in China costs $40,000–$80,000 — a fraction of the estimated $100,000–$150,000 for comparable treatment in the US under private pay.
• High surgical volume: Chinese neurosurgery centers have performed more implant surgeries than any single Western institution, building surgical and calibration expertise rapidly.
• Trial participation: The new fully implantable multi-center trial may accept international patients who meet the inclusion criteria.

Top Hospitals for BCI Treatment in China

These are the most active Chinese centers for BCI research and clinical implantation:

• Beijing Tiantan Hospital (Capital Medical University) — Major neurosurgery center and one of the China Brain Project's lead institutions; BCI trial site for the 2026 fully implantable study
• Huashan Hospital, Shanghai (Fudan University) — NeuroXess implant center; one of China's highest-volume neurosurgery departments; active international patient services
• Zhejiang Provincial People's Hospital, Hangzhou — Trial site for the May 2026 fully implantable BCI study; established rehabilitation engineering unit
• Chinese Academy of Sciences Institute of Neuroscience — Research partner for BCI electrode development and neural signal decoding algorithms

The Treatment Process

For international patients, the BCI journey in China typically follows this path:

• Pre-arrival (remote, 2–4 weeks): Submit medical records including MRI/CT scans on disc, neurological examination findings, and a description of prior rehabilitation history. The hospital's BCI team reviews and determines whether the patient meets trial or treatment criteria.
• Arrival and assessment (3–5 days): In-person neurological assessment, MRI mapping, and BCI trial fitting (non-invasive pre-screening to confirm the patient can control a BCI signal before committing to surgery).
• Surgery day: 4–8 hours under general anesthesia. Craniotomy for electrode placement, chest implant for processor.
• Post-operative stay (7–14 days): Initial recovery, wound monitoring, first calibration sessions. The BCI team begins signal mapping — identifying which neurons correspond to intended movements.
• Calibration period (4–8 weeks post-discharge): Most intensive rehabilitation phase. Patients learn to control external devices (FES systems, computer cursors, or wheelchairs) through thought. Remote calibration sessions continue after the patient returns home.
• Long-term: Annual follow-up visits or remote check-ins. The device is designed to remain functional for decades; lead replacements may be needed in 5–10 years.

BCI Implant Comparison: China vs US vs Other Markets (2026)

Data sources: NMPA announcements (March 2026), Neuralink PRIME-IT trial data, Synchron FDA 2024 approval, research from China Brain Project published in Nature Neuroscience (2025).

Patient Decision Guide: Is BCI Implantation in China Right for You?

Who Should Consider BCI Treatment in China

• Patients with cervical spinal cord injury (C3–C7) who have preserved motor cortex function and have completed standard rehab without achieving functional hand recovery
• Stroke patients with chronic hemiplegia (6+ months post-stroke) who have hit a plateau with conventional occupational and physical therapy
• ALS patients with preserved cognition who want augmentative communication options before they lose speech
• Patients who cannot access BCI trials in their home country and want to be among early recipients of approved or trial-stage technology
• Patients who can afford $40,000–$80,000 total cost and want to avoid the multi-year wait times in US/European programs

Who Should NOT Come to China for BCI Implantation

• Patients with severe cognitive impairment or dementia that would prevent them from learning BCI control — the device requires active participation in calibration
• Patients with active infections, severe osteoporosis, or other conditions that make neurosurgery prohibitively risky
• Patients whose paralysis is not caused by a condition with an established BCI indication (e.g., peripheral nerve injury alone — BCI does not directly address this)
• Patients expecting immediate, seamless results — BCI calibration is a weeks-long process that requires motivation and practice

What to Prepare Before Arrival

• MRI of the brain and spine (DICOM files on disc): The team needs to confirm that the motor cortex is intact and suitable for electrode placement
• Neurological evaluation report: Documenting ASIA classification (for spinal cord injury) or Fugl-Meyer score (for stroke)
• Rehabilitation history: A summary of therapies tried and functional outcomes achieved — this helps the team assess realistic expectations
• Medical visa: International patients typically apply for an S1 visa (long-term medical stay, 3–12 months, renewable) with the hospital's invitation letter
• Caregiver: BCI calibration requires a second person — either a family caregiver or hired accompaniment — for the first several weeks

Estimated Total Cost for International Patients

• Surgery and device (Neurecell ACL-BCI-1 or equivalent): $30,000–$60,000 depending on device generation and hospital tier
• Hospitalization (10–14 days in international ward): $5,000–$15,000
• Initial calibration and rehab (4–8 weeks): $3,000–$8,000
• Flights (round-trip, most origins): $1,000–$4,000
• Accommodation (6–10 weeks, mid-range hotel or serviced apartment): $1,500–$4,000
• Medical visa, translation, coordinator services: $500–$1,500
• All-in estimate for BCI treatment in China: $45,000–$90,000 total — compared to $100,000–$150,000+ estimated for equivalent US commercial treatment

Frequently Asked Questions

Is BCI implantation in China safe? What are the risks?

The main surgical risks are infection (managed with intravenous antibiotics and sterile technique), bleeding (occurs in 1–3% of craniotomies), and neurological complications (rare, <1% in published Chinese BCI series). The non-implantable Neurecell ACL-BCI-1 has been used in patients since 2024 with a favorable safety profile. The fully implantable device is newer and will be monitored closely through the current trial.

Can international patients participate in China's BCI trials?

Some international participation may be possible depending on the specific trial's inclusion/exclusion criteria and whether the sponsor (a Chinese university or company) has provisions for international patients. Contact the hospital's international patient department directly with your medical history for a definitive answer. The approved Neurecell ACL-BCI-1 device is available to international patients at certain centers on a self-pay basis.

What can a patient actually do after BCI implantation?

Outcomes vary. In published NeuroXess cases, patients who were tetraplegic (full paralysis of all four limbs) regained the ability to control a computer cursor, play simple video games, and operate a wheelchair through thought after calibration. The best results require weeks of practice. Restoration of hand grasp — the ability to pick up a cup or bottle — is a realistic goal for many cervical spinal cord injury patients.

How does China's BCI compare to Neuralink?

Both target the motor cortex for signal decoding. Neuralink uses a flexible polymer thread array with 1,024 electrodes (higher resolution) and its own proprietary surgical robot. China's main commercial option (Neurecell ACL-BCI-1) uses a different electrode design with fewer channels but already has NMPA approval — Neuralink has not yet received FDA commercial approval. The new fully implantable trial in China is targeting higher channel counts to close the gap.

Does insurance cover BCI treatment abroad?

Most international health insurance plans do not cover treatment sought abroad, and no plan currently covers BCI implantation as a standard benefit. However, some international patient assistance programs and catastrophic coverage policies may reimburse a portion of costs. Check with your insurer before assuming non-coverage. Some patients pursue BCI treatment as self-pay and seek reimbursement afterward.